GT Biopharma Inc at HC Wainwright Cell Therapy Virtual Conference Transcript
Welcome to our next presentation. I'm Robert Burns, a Managing Director and Senior Biotech Analyst at H.C. Wainwright. I'm joined today by Michael Breen, the CEO of GT Biopharma; and Dr. Jeffrey Miller, the consulting CMO and CSO of GT Biopharma. With that said, Dr. Miller, take it away.
Great. Thank you very much. So today, I'm going to talk a little bit about our tri-specific NK cell engagers, or TriKEs, as we refer to them. Here's our forward-looking statement. So as a very brief introduction, what we have developed here is a camelid nanobody TriKE platform.
The importance of these NK cell engagers is a couple of things, and we'll get through this as I go through the data. But I wanted people to realize that these are protein engagers. And these are not cell therapies, which are very, very different. The thing that's very unique about our platform is that on the NK cell side, we engage two
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)